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Summary
Objective: Several research groups have examined osteoarthritis (OA) association with Interleukin-1 (IL-1) region markers and haplotypes.
The results have been suggestive for hand OA, negative for knee OA, and conﬂicting for hip OA.
Design: Our aim was to address conﬂicts employing meta-analytical methods on data from 1238 European-descent cases with various OA
phenotypes and 1269 European-descent controls from four study centers. We imputed some missing genotype data and reconstructed
IL-1 region extended haplotypes. A previously reported 7-marker IL1A-IL1B-IL1RN extended risk haplotype was tested for association with
each speciﬁc index phenotype.
Results: For hip OA, data from three centers showed heterogeneity of extended-risk-haplotype effect, two panels showing trend toward risk
and another showing protection, with overall odds ratio (OR) 1.24 (95% Conﬁdence interval (CI) 0.45e3.41, P 0.67). The heterogeneity fell
partly along control ascertainment lines, chieﬂy between controls ascertained as spouses of arthroplasty patients and controls identiﬁed
through population radiographic survey. For knee OA, the results showed no heterogeneity and no signiﬁcant extended-risk-haplotype effect.
For hand OA, the results showed little heterogeneity and a modest trend toward positive association (summary OR 1.34, 95% CI 0.83e2.17
P 0.23). Using a Bayesian partition modeling approach, the 7-marker extended haplotypes showed no signiﬁcant effect on any OA phenotype
examined. A 3-single-nucleotide polymorphism (SNP) IL1B-IL1RN haplotype rs1143627ers16944ers419598 showed a trend toward hand
OA association (posterior probability of association 0.72) with the most prominent feature being protection from a speciﬁc haplotype represent-
ing a partial mirror image of the extended risk haplotype (OR estimated at 0.46).
Conclusions: The meta-analysis data do not conﬁrm but only suggest that some hand and hip OA risk could be associated with the IL-1 region,
particularly centered in IL1B and possibly also IL1RN.
ª 2009 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.
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Osteoarthritis (OA) is a late-onset disorder with important
heritable1e3 and random/environmental contributions such
as physical workload (hip and knee OA), high-intensity
sporting activity (hip OA), and being overweight or obese
(clinical hip OA)4. Other contributions to various OA pheno-
types include sex, possibly severe degrees of mal-align-
ment, and joint injuries such as meniscectomy in knee OA
or intra-articular fractures5. Experimental evidence entwines
Interleukin-1 (IL-1) with deleterious mechanisms in early
and late OA stages (reviewed in6e9). OA-affected cartilage
bears ﬁndings consistent with a harmful imbalance between
IL-1 and IL-1 control proteins10,11. Blocking IL-1 may pre-
vent experimental OA12e15 and retard early OA*Address correspondence and reprint requests to: G. Moxley,
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200progression16e18. Finally, human subjects grouped by high-
est quartile of in vitro lipopolysaccharide (LPS)-stimulated
IL-1b and IL-1Ra had an increased OA risk, which in turn
would suggest that variations in innate cytokine production
may inﬂuence OA liability19. Taken as a whole, this evi-
dence suggests that the IL-1 region may contain OA candi-
date genes.
Family-based studies have shown conﬂicting evidence
about linkage with the IL-1 region20e26; one might rational-
ize lackluster linkage results by arguing that linkage study
design is insufﬁciently powerful for the various OA pheno-
types. Yet neither have caseecontrol studies supported as-
sociation resoundingly with any OA phenotype. The IL-1
region data have conﬂicted among hip OA studies27e30.
Knee OA studies overall have been minimally supportive
or negative29,31e36. One hand OA study showed associa-
tion37 and another was inconclusive29. One may sometimes
strengthen association evidence through meta-analytical
study methods that aggregate individual study effects, and
meta-analyses have produced strong evidence for two OA
201Osteoarthritis and Cartilage Vol. 18, No. 2genes, GDF5 and DIO238,39. We therefore sought to re-
solve conﬂicts and perceive trends through further analyses
of all known available IL-1-genotyped European-descent
OA cases and controls, including meta-analyses.Materials and methodsSUBJECTSThe projects on which these analyses are based were approved by the
appropriate research ethics committees, and all subjects gave informed con-
sent for the studies. The research subject samples have each been previ-
ously outlined in prior publications from the participating centers (the
Rotterdam sample reported from Leiden, Oxford, Bristol, and Rich-
mond)27e32,37,40. Table I outlines classiﬁcation criteria and salient panel
characteristics. For this study, the Rotterdam panel subset with three or
more radiographically affected hand joints were classiﬁed as affected to align
the deﬁnition with the Richmond panel. None of the research group leaders
were aware of any other genotyped European-descent caseecontrol sam-
ples in unpublished work or from other centers. We aimed toward obtaining
data about potential confounders, yet data were constrained to those avail-
able from individual centers. N¼ 391 subjects had sex data unavailable,
n¼ 1572 had no age speciﬁed, and for body mass index, n¼ 1645 had miss-
ing data. Available radiographic data were presence or absence of classiﬁed
radiographic OA by criteria deﬁned in the individual studies.MOLECULAR GENETIC TYPINGThe genotyped markers of interest were those deﬁning a 7-marker IL-1 re-
gion risk haplotype that had been associated with hip OA previously27e30
and included IL1A (rs1800587 (commonly termed 889)), IL1B
(rs1143634 (þ3958)ers1143627 (31)ers16944(511)), and IL1RN
(rs419598 (8006)eintron 2 variable number of tandem repeat
(VNTR)ers315952(11100)). For the Oxford panel ILB rs1143634, 1.0% of
genotype data were missing, rs1143627 84.2%, and rs16944 6.7%, and
for IL1RN, rs419598 100%, intron 2 VNTR 79.4%, and rs315952 6.0%.
Thus, many Oxford specimens lacked genotypes for IL1B rs1143627, or
IL1RN rs419598, or IL1RN intron 2 VNTR, or both IL1RN markers, but
IL1B rs16944 and IL1RN rs454078 genotypes (IL1RN þ9589) were avail-
able (with 1.9% missing genotypes). Among the non-Oxford samples, the
linkage disequilibrium (LD) measure D0 was 0.99 between rs1143627 and
rs16944. To lend support for imputing genotypes of rs419598, we addressed
genotyping for rs419598 to conﬁrm degree of LD. Forward and reverse oligo-
nucleotide primers for rs419598 were obtained from MWB (now Euroﬁns
MWG Operon, London) (50 ATG TGG GCT CAC TGC TCA C-30 and 50-
CCT CTC CAC ACC CTC TTC AG-30, respectively), and used to amplify
a 510-bp product that was subjected to MspI restriction digestion followed
by electrophoresis in 2% agarose/1X TBE gels with ethidium bromide stain-
ing. Where the rs419598C minor allele was present, the polymerase chain
reaction (PCR) product was cut to form 276- and 234-bp restriction frag-
ments. Thus, a polymerase chain reactionerestriction fragment length poly-
morphism (PCR-RFLP) method was used to assign rs419598 genotypes for
a subset of Oxford subjects. Table II presents data for frequencies of individ-
ual markers and genotypes.STATISTICAL ANALYSESMost statistical tests were done by R-software-based packages. Contin-
gency tables were analyzed by c2 analyses. LD was analyzed using the R
software package genetics, single-locus tests used glm with simulated P
values (Monte Carlo simulation with 200 replicates), and meta-analyses
were done with packages meta and rmeta. For the meta-analytical analyses,
each panel’s sum of probable 7-marker risk haplotypes and sum of all other
probable haplotypes for cases and controls was used as entry data (see
Fig. 1). The ManteleHaenszel method assumes ﬁxed effect, that all studies
have a common effect, and provides a pooled odds ratio (OR) appropriate for
study data lacking heterogeneity through weighting by inverse of within-study
variance. The DerSimonian & Laird method assumes random effects, that in-
dividual studies may have different effects, and provides a pooled OR more
suitable among heterogeneous studies by weighting using an inverse of
combination of within-study and between-study variance. Higgins’ I2 was cal-
culated to assess degree of heterogeneity41,42. Extended haplotypes were
reconstructed using PHASE 2.143,44, and individual extended haplotype fre-
quencies are represented in Table III. Following the method of Sham et al.45
we tested for the effects of the 15 haplotypes on the IL-1 and OA pheno-
types. Using Mx46 we ﬁtted mixture distribution models to account for the un-
certainty of the individual haplotypes due to homozygosity at one or more of
the single-nucleotide polymorphism (SNP) loci. The difference in minus twicethe log-likelihood between one model with haplotype means estimated and
another without may be interpreted as a chi-squared statistic with degrees
of freedom equal to the difference in the number of parameters of the two
models. In the present context, the diagnostic data were treated as binary,
on the assumption of an underlying mixture of normal distributions with
a threshold above which individuals are affected. Bayesian partition model-
ing (BPM) was also done to assess strength of haplotype association (GEN-
EBPM software v. 2.0)47. Because BPM limits entry data to 2000 individual
sets of genotypes, randomly generated numbers were used to thin the
knee OA entry data from 2075 and hip OA from 2086 to 2000.ResultsLD AND IMPUTATION OF MISSING GENOTYPESIn a large fraction of Oxford samples, rs419598 and
IL1RN intron 2 VNTR data were missing yet rs454078 ge-
notypes were available. We had noted that the International
HapMap project had included both rs419598 and rs454078,
and based on relatively small numbers of typed individuals,
found high degrees of LD between the two. The Oxford
group had previously reported complete LD between
rs454078 and the IL1RN intron 2 VNTR32. Similarly, using
all individuals for whom IL1RN intron 2 VNTR genotypes
were available apart from the Oxford panel, LD was high be-
tween rs419598 and the IL1RN intron 2 VNTR (D0 0.94 and
r2 0.80). Using MspI PCR-RFLP method to genotype
rs419598 for n¼ 204 Oxford panel individuals that had al-
ready been typed for rs454078, the LD between rs419598
and rs454078 was conﬁrmed to be high (D0 0.987,
r2 0.973), with both major alleles together and both minor
alleles together on respective haplotypes. With this back-
ground, the rs419598 and VNTR genotypes were imputed
for the remaining Oxford subjects; the minor allele at
rs454078 was used to impute minor allele at rs419598
and IL1RN intron 2 VNTR allele *2. Among all subjects,
the rare IL1RN VNTR alleles *3 and *4 were pooled with
*1. For all panels, missing genotypes at rs1143627 (IL1B-
31) were imputed from rs16944 (IL1B-511), and vice versa.
Among all subjects, the various IL-1 region markers had
statistically signiﬁcant LD of various degrees (Table IV).
The LD data in Table IV suggest that D0 exceeds 0.7 among
IL1B SNPs and 0.7 among IL1RN markers; between IL1B
rs16944 and the nearest IL1RN SNP rs419598, the D0 is
lower and approximates 0.39. The pattern of limited LD
among loci would mean that ancestral recombination has
been frequent across this large interval, and therefore
many extended haplotypes exist.SINGLE-LOCUS ANALYSES FOR ASSOCIATION WITH OA
PHENOTYPESThe Rotterdam, Bristol, and Oxford panels had data about
hip OA phenotype, but we found that no single IL1A, IL1B,
or IL1RN marker showed association using either an addi-
tive or genotypic model on the combined data. For knee
OA, phenotype data were available from Rotterdam, Bris-
tol/London, and Oxford panels, but no IL-1 region marker
showed association. For hand OA, only Rotterdam and
Richmond panels had phenotypes available. When exam-
ined with logistic regression, the IL1B rs1143627 and
rs16944 promoter SNPs showed a trend toward hand OA
association (uncorrected P values 0.04 and 0.03, respec-
tively). The results were consistent with either multiplicative
(i.e., log additive) or genotypic models, but the multiplicative
models ﬁt better (for the two respective SNPs, the Akaike’s
Information Criterion comparison (AIC) for additive vs multi-
plicative was 1051.3 vs 1052.8, and 1015.7 vs 1016.9). The
Table I
Characteristics of panels included in meta-analyses
Study Number in
meta-analyses
Geographic
ancestry
Sex (F:M) in
meta-analyses
Case recruitment
setting
Case index
phenotype
Case age
(years, mean SD,
except as noted)
Control phenotype Control age
(years, meanSD,
except as noted)
Smith et al.27,31 Knee OA Bristol
164 and London
158, hip OA 20,
controls 184
United Kingdom
Caucasian
Bristol knee OA
74:59 (31 not
available), London
knee OA (none
available), hip OA
6:7 (7 unavailable),
controls unavailable
(98:97 reported31)
Knee OA from
rheumatology
outpatient clinics,
hip OA from
orthopaedic center
Knee OA by
radiographic
criteria, hip OA by
revision or primary
arthroplasty
Bristol knee OA
mean 62, London
knee mean 71,
hip OA median 71
(no SD available)
Volunteer blood
donors (Southwest
England)
Range 18e55
(meanSD not
available)
Meulenbelt
et al.28,29
Knee OA 133,
hip OA 69,
hand OA 163,
(hip-knee 16,
hip-hand 15,
hip-knee-hand
15, knee-hand 41)
controls 465
Dutch Caucasian
(Rotterdam)
Hip OA 28:41,
knee OA 97:36,
hand OA 125:38,
Controls 256:209
Random sample of
persons aged
55e65 years in
prospective
population-based
cohort survey
Radiographic hip,
knee, or hand OA
(3 joints or more)
Hip OA 60.7 2.6,
knee OA 60.8 2.6,
handOA62.1 2.229
Absence of
radiographic OA
59.5 2.729
Stern et al.37,40 Hand OA 51 USA Caucasian
(Virginia)
Hand OA 40:11,
Controls 8:44
Large Department
of Veterans Affairs
hospital
Radiographic hand
OA (3 joints or more)
67.6 9.9 Medical clinic
outpatient, absence
of hand OA signs
73.1 6.9
Loughlin et al.30,32 Controls 557,
hip OA 163,
knee OA 414,
(hip-knee 30)
United Kingdom
Caucasian (Oxford)
Hip OA 95:68,
Knee OA 260:154,
Controls 341:216
Large public
musculoskeletal
disorder hospital
Arthroplasty
procedure for hip
and/or knee OA,
and spouse without
OA treatment
Mean 72.832
(SD not available)
Spouses of cases
without arthroplasty
or OA treatment
Mean 72.832
(SD not available)
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Table II
Individual marker genotype and allele frequencies summed among all panels*
rs1800587 rs1143634 rs1143627 rs16944 rs419598 IL1RN VNTR rs315952
Allele frequency
All controls *1 0.702 0.762 0.665 0.662 0.733 0.723 0.713
*2 0.298 0.238 0.335 0.338 0.267 0.277 0.287
Genotype frequency
Phenotype rs1800587 rs1143634 rs1143627 rs16944 rs419598 IL1RN VNTR rs315952
Any OA gt1,1 574 725 567 567 631 638 650
gt1,2 531 427 538 539 478 480 458
gt2,2 109 72 127 126 84 113 117
Hip OA gt1,1 119 146 98 99 125 126 130
gt1,2 105 85 127 127 100 104 96
gt2,2 23 14 26 25 17 21 22
Knee OA gt1,1 409 510 403 403 439 446 459
gt1,2 369 301 368 369 350 343 319
gt2,2 79 51 92 91 57 78 86
Hand OA gt1,1 98 126 106 105 111 114 109
gt1,2 95 76 87 87 63 75 81
gt2,2 13 10 21 22 17 21 20
Controls gt1,1 593 733 555 550 638 665 644
gt1,2 546 460 574 578 469 494 501
gt2,2 94 71 138 139 83 103 110
*gt1,1 homozygous genotype of major allele, gt1,2 heterozygous genotype, gt1,1 homozygous genotype of minor allele. Numbers represent
the sum of speciﬁc genotypes represented in each phenotypic group. N. b.: because genotyping was not accomplished for every marker in
every subject, not all sums of genotypes equal the total subject numbers.
Fig. 1. Meta-analytic overview of OA phenotypes according to data about extended haplotype formed by IL1A (rs1800587), IL1B
(rs1143634ers1143627ers16944), and IL1RN (rs419598eintron 2 VNTRers315952). ‘‘Panel’’ indicates primary site of study panel. ‘‘Risk
Eht’’ is the 7-marker extended haplotype 1111221 representing major alleles at all loci except rs419598 and intron 2 VNTR that has previ-
ously been reported as associated with hip OA and with hand OA. ‘‘DSL OR’’ is DerSimonian & Laird OR for random effects49 and ‘‘MH OR’’
ManteleHaenzel OR, both as implemented in R software package meta. Numbers representing probable risk extended haplotypes and total
7-marker extended haplotypes are the summed probabilities within each OA phenotype or control group. Q represents Cochran’s test for
study heterogeneity between or among panels and is tested as c2 with df, degrees of freedom. I2 is Higgins & Thompson’s index reﬂecting
variation attributable to study heterogeneity (low< 25%, medium 25e75%, high> 75%41,42). Each panel’s OR is graphically indicated by
position of square and 95% CI by line; study weighting is shown by size of square for each panel; and each summary OR and CI are indicated
by the diamond’s respective center and horizontal dimension. All summary ORs have CIs overlapping unity and therefore are not statistically
signiﬁcant.
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Table III
Extended IL1A-IL1B-IL1RN Haplotypes by panel and phenotype
EHT1y EHT2 EHT3 EHT4 EHT5 EHT6 EHT7 EHT8 EHT9 EHT10 Other
All controls* Frequency 0.2 0.111 0.068 0.101 0.028 0.109 0.019 0.08 0.077 0.02 0.165
Phenotype Panel EHT1y EHT2 EHT3 EHT4 EHT5 EHT6 EHT7 EHT8 EHT9 EHT10 Other
Control Rotterdam 179.1 110.8 46.8 99.1 31.8 89.4 13.1 73.3 82.1 12.5 192.00
Control Bristol 75.5 38 32 42.4 8.2 47 10.9 32.3 21.4 8.4 74.00
Control Richmond 22.5 11.2 5.2 13.9 2.2 18 3.8 6.9 4.4 4 11.90
Control Oxford 240.8 128.3 91.8 106 30.2 129.1 22.7 95.8 92.2 27.4 149.60
Any OA Rotterdam 121.8 74.3 36.6 55.6 14 69.7 11.6 44.5 50.9 8.9 108.20
Any OA Bristol-London 127.9 71.2 59.6 52.2 21.5 72.1 17 59.9 37.1 19.1 146.40
Any OA Richmond 25.4 10.7 8 9.2 2.2 18.2 1 8.2 7.6 1.3 10.20
Any OA Oxford 237 134.6 66.3 104.9 34.4 123.7 26.6 103.2 85.7 17.6 160.00
Hip OA Rotterdam 24 13.6 14.1 19.6 6.7 21.4 2.4 7.2 8.4 1.7 18.90
Hip OA Bristol-London 4.5 2.6 5.8 4.3 0.7 4.7 1.2 1.7 1.6 1 11.90
Hip OA Oxford 73.9 31.7 14.3 31 8.5 41.5 6.8 29.1 39.4 5.2 44.60
Knee OA Rotterdam 51.8 32.5 10.9 24.3 5.2 31.6 5.7 19 23.9 4.3 56.90
Knee OA Bristol-London 123.4 68.6 53.8 47.9 20.8 67.4 15.8 58.2 35.5 18.1 134.50
Knee OA Oxford 179.1 111.5 54.6 78.6 27 90.1 21.5 75.5 56.3 13 120.90
Hand OA Rotterdam 70.3 44 20.8 27.7 4.9 34.8 6.5 26.5 30.5 4.7 55.40
Hand OA Richmond 25.4 10.7 8 9.2 2.2 18.2 1 8.2 7.6 1.3 10.20
*Frequencies of extended haplotypes are represented in ﬁrst line for all control groups. The common extended haplotypes were coded
1e10 as EHT1 1111111, EHT2 1111112, EHT3 1111221 (nominal extended risk haplotype), EHT4 1122111, EHT5 1122112, EHT6
1122221, EHT7 2122221, EHT8 2211111, EHT9 2211112, and EHT10 2211221.
yPHASE software predicted probabilities for n¼ 46 distinct extended haplotypes, many individually rare. To allow c2 analyses among
panels and phenotypes without interference from low cell frequencies, we used eleven categories composed of the ten common extended
haplotypes noted above, plus an eleventh pool of the remaining individually rare extended haplotypes. The numbers in the table represent
the sum of PHASE-estimated probabilities in the individual panel and phenotype; n. b.: because of rounding errors in individual probabilities,
not all sums of extended haplotype probabilities equal whole numbers.
204 G. Moxley et al.: IL-1 Region meta-analysis with OAgenetic effect strength was relatively modest (OR 0.78 for
each minor allele at rs1143627 and OR 0.77 at rs16944).
Each SNP’s effects were dependent on the other, consis-
tent with strong LD. No other individual IL-1 region marker
showed association with hand OA.ANALYSIS USING 7-MARKER EXTENDED HAPLOTYPESThe analyses showing relatively low LD between IL1A
rs1800587 and IL1B rs1143627, and between IL1B
rs16944 and IL1RN 419598 (Table IV), would argue against
extended haplotypes across IL1A, IL1B, and IL1RN. Never-
theless, because of previous reports27e30, we examined the
extended IL-1 region haplotype for association. Using
PHASE 2.1 on unphased genotype data, we derived the
IL1A-IL1B-IL1RN extended haplotypes for all subjects.
Then the frequency distribution of extended haplotypes
was examined between cases and controls. Using the 10Table I
LD among IL-1 reg
IL1B rs1143634 IL1B rs1143627 IL1B rs1
IL1A rs1800587 D0 0.82 0.38 0.3
P <2.2e16 <2.2e16 <2.2e
IL1B rs1143634 D0 0.70 0.7
P <2.2e16 <2.2e
IL1B rs1143627 D0 0.9
P <2.2e
IL1B rs16944 D0
P
IL1RN rs419598 D0
P
IL1RN intron 2 VNTR D0
Pmost common extended haplotypes with an eleventh
pooled category for all others (the sum of those extended
haplotypes bearing estimated frequencies 0.01 or lower,
as in Table III), the extended haplotype distribution was dif-
ferent among the four control panels (c2 56.1, simulated
P 0.003). The major differences reﬂected a deviation be-
tween the Oxford and Rotterdam control panels (c2 33.1,
simulated P 0.001). The major c2 contributions were from
control cells representing the pooled uncommon extended
haplotypes (relatively more in the Rotterdam panel than in
the Oxford control panel, frequency 0.206 vs 0.134) and
secondarily in the extended risk haplotype 1111221 (rela-
tively fewer in Rotterdam controls than in Oxford controls,
frequency 0.05 vs 0.082). The Oxford control frequencies
deviated little from Bristol-area blood donor controls (c2
12.4, simulated P 0.25). For hip OA cases, there was a trend
toward difference among the three panels (c2 31.0, P 0.056)
with relatively more extended risk haplotypes in theV
ion markers
6944 IL1RN rs419598 IL1RN intron 2 VNTR IL1RN rs315952
9 0.24 0.28 0.12
16 1.03E-08 4.44E-13 4.00E-13
1 0.58 0.64 0.21
16 <2.2e16 <2.2e16 <2.2e16
9 0.39 0.38 0.38
16 <2.2e16 <2.2e16 <2.2e16
0.39 0.39 0.38
<2.2e16 <2.2e16 <2.2e16
0.97 0.70
<2.2e16 <2.2e16
0.70
<2.2e16
205Osteoarthritis and Cartilage Vol. 18, No. 2Rotterdam and Bristol panels (respective frequencies 0.102
and 0.145) and fewer in the Oxford group (0.044, even
lower than in Oxford controls). We examined whether im-
puting missing genotypes would have changed the analyti-
cal outcome but found no signiﬁcant change in outcome
with alternative assumptions. Thus, overall extended haplo-
type distribution tended to differ, particularly between the
Rotterdam and Oxford hip OA cases and between Rotter-
dam and Oxford controls.META-ANALYSES WITH EXTENDED RISK HAPLOTYPEThe IL-1 region extended risk haplotype 1111221 was
then employed in meta-analyses for each OA index pheno-
type (hip OA, knee OA, or hand OA). To allow for uncer-
tainty regarding predicted haplotypes derived from
heterozygous individuals, we used probabilities for all po-
tential predicted haplotypes instead of the pairs of most
probable haplotypes. Figure 1 shows numbers representing
summed probable extended risk haplotypes and total ex-
tended haplotypes for OA and control panels for each index
phenotype. For the three panels with hip OA comparisons
(Bristol, Rotterdam, and Oxford), the Cochran’s Q statistic
testing whether effects were similar among studies was
consistent with among-study heterogeneity (P 0.0018),
and I2 value was consistent with high degree of heterogene-
ity. The major heterogeneity emanated from differences be-
tween the Oxford panel and the other two; using meta-
analytic inﬂuential analysis, I2 was 0% after omission of Ox-
ford hip OA cases and controls, and the summary OR for
the other two panels was 1.94 (95% Conﬁdence interval
(CI) 1.22e3.10, P 0.005). Because of the heterogeneity
among hip OA studies, the DerSimonian & Laird method al-
lowing for random effects among studies was used to sum-
marize overall effect. There was a trend toward risk in
Bristol and Rotterdam panels (ORs 1.90 and 2.15, respec-
tively), and protection in the Oxford panel (OR 0.51), and
the DerSimonian & Laird summary OR was consistent
with some genetic effect (OR 1.24). For the index pheno-
type knee OA, there was little evidence of heterogeneity
among studies, and ManteleHaenzel and DerSimonian &
Laird summary ORs were identical at 0.86 (95% CI
0.66e1.10). For the Rotterdam and Richmond panels with
index phenotype hand OA, the individual OR estimates
were 1.29 and 1.62 with identical ManteleHaenzel and Der-
Simonian & Laird summary ORs 1.32 (95% CIs 0.84e2.08).
CIs for summary ORs in all phenotypes overlapped unity.
Thus, OA risk stemming from 7-marker extended risk hap-
lotype differed by OA phenotype: the three hip OA panels
showed heterogeneity with the best overall estimate consis-
tent with some genetic effect, knee OA panels appeared
completely negative, and hand OA studies showed no het-
erogeneity and some possible modest risk.MX AND BPMIn view of LD patterns (Table IV), one could argue that as-
suming association with a single extended haplotype
1111221 within an extended region bearing frequent ances-
tral recombination could hide a true association, and there-
fore we sought to analyze the data without a priori
assumptions. One method was Mx modeling with extended
haplotype probabilities as estimated using PHASE using
a phenotype deﬁnition of any OA. We ﬁtted the mixture dis-
tribution model with 15 haplotype means to the data, which
yielded a 2 lnL of 1312.17. As a global test, the 15haplotype means were set to zero, which resulted in
a change of 2 lnL (i.e., chi-squared) of 15.13 with 15 df,
P< 0.45, which is non-signiﬁcant. There was no evidence
of signiﬁcant heterogeneity among the haplotype means
in these data. However, this method may estimate some
haplotype means with little statistical power, because the
sample size is small. Therefore, we tested for each haplo-
type mean effect individually in other models. None of these
tests was signiﬁcant. Another method was BPM, a method
using unphased genotype data to assess association
strength and estimates of haplotype relative risks47; it
does not assume a priori that any speciﬁc haplotype or ex-
tended haplotype has a disease association. Using IL1B
SNPs or IL1RN markers to deﬁne 3-marker IL1B or
IL1RN haplotypes, respectively, the posterior probabilities
indicated poor ﬁt for hand, knee, or hip OA (BPM posterior
probabilities 0.34e0.45). With the 7-marker extended IL1A-
IL1B-IL1RN haplotypes, there was no evidence of effect on
hip or knee OA (posterior probabilities 0.38 and 0.35, re-
spectively). For hand OA, the 7-marker extended haplotype
analysis showed posterior probability of association 0.60,
consistent with minimal trend toward association. The so-
called extended risk haplotype 1111221 conferred no extra
risk (OR 1.00 relative to the most common haplotype), but
the extended haplotypes 1122111, 1122112, 2222112,
and 2122111 conferred protective effects averaging OR
0.81. When the deﬁned haplotype was trimmed to the three
IL1B markers with the closest two IL1RN markers, the pos-
terior probability was 0.69 with protective OR for the haplo-
types 12211 and 22211 (OR 0.58 relative to the most
common haplotype). Using a further distillation to the three
markers IL1B rs1143627eIL1B rs16944eIL1RN rs419598
with hand OA, the 221 haplotype (estimated frequency
0.19) trended toward a protective effect (posterior probabil-
ity 0.69, OR 0.77 relative to the most common haplotype).
Neither hip OA nor knee OA showed association with the
same 3-SNP IL1B-IL1RN haplotype (posterior probabilities
0.37 and 0.38, respectively). Therefore, the BPM method
found only minimal evidence of hand OA association, with
the most salient feature a protective effect formed by a spe-
ciﬁc IL1B-IL1RN 221 haplotype that represents the mirror
image of the middle three markers along the reported IL-1
region extended risk haplotype 1111221.Discussion
Taken as a whole, this meta-analysis did not settle the
central question about whether a common IL-1 marker or
haplotype inﬂuences one or another OA phenotype. The
cases and controls represented here are not new, and so
this is not a replication, but an attempt toward further deﬁni-
tion. For hip OA, meta-analysis shows heterogeneity and
some trend toward an overall association with IL-1 region
extended risk haplotype. Knee OA demonstrates no genetic
effect from the IL-1 region at all, and hand OA data appear
to show possible association with IL-1 region extended risk
haplotype that, by BPM, could truly represent a protective
effect at two IL1B SNPs and possibly extending toward
IL1RN. These data cannot disprove IL-1 role in OA, be-
cause individually rare variants likely to lie on various hap-
lotypes might play a role, and common variants with modest
genetic effects might be missed with this sample size and
limited marker genotypes available.
The reason for heterogeneity among hip OA studies is
unknown. One simple explanation is chance or random
effect. In support of no effect, the meta-analyses show
206 G. Moxley et al.: IL-1 Region meta-analysis with OAoverlap of summary OR with unity for all three OA pheno-
types, and BPM results suggested no association for hip
or knee OA. On the other hand, were a true genetic effect
present, among-study heterogeneity could reﬂect clinical
details of case and control ascertainment. The hip OA study
ascertainment issue is not so simple as a case difference
between hip arthroplasty and population radiographic sur-
vey, because the cases did not differ between radiographi-
cally-screened Rotterdam and arthroplasty-ascertained
Bristol panels (P 0.70) but did between Oxford and Bristol
arthroplasty-ascertained panels (P 0.05). Instead, the
meta-analytic heterogeneity was more related to control
ascertainment among Dutch radiographically-screened
subjects, Bristol-area blood donors, and Oxford artho-
plasty-patient spouses. The Rotterdam study had the virtue
of characterizing cases and controls in identical ways for
hip, knee, and hand OA. The OA-relevant information dif-
fered between cases and controls in the other two hip OA
centers. Both the blood donor and arthroplasty-spouse-con-
trol ascertainment methods potentially could have enlisted
individuals deemed unaffected but destined to develop
OA or having OA, blood donors because of ascertainment
before OA onset age, and arthoplasty-patient spouses
related to information bias. Also, spouse controls differ sys-
tematically in sex effect and likely also in other OA contrib-
utory factors like joint loading. Yet the largest difference
between Rotterdam and Oxford controls seemed to ema-
nate from the extended haplotype cells representing pooled
uncommon extended haplotypes, which might herald pres-
ence of undetected genetic inﬂuences paralleling ascertain-
ment differences from the respective geographic areas. At
this juncture, one cannot disentangle the factors responsi-
ble for hip OA study heterogeneity. Even if the association
between hip OA and IL-1 region was true, with such study
heterogeneity, it might not be practical to replicate the
extended-risk-haplotype association with consistency48.
Yet another potential explanation is that only part of the
extended haplotype confers risk, and ancestral recombina-
tion along the extended haplotype would interfere with
detection. Were this the case, individuals bearing ances-
trally recombined chromosomes might bear the true risk
region but not be counted as having the extended risk
haplotype and thereby dilute true genetic effect and power.
The two hand OA studies tend to support IL-1 region as-
sociation with IL1B markers rs1143627 and rs15944, possi-
bly extending to the IL1RN region as a haplotype
rs1143627ers15944ers419598, with the most likely picture
being modest protection provided by a segment represent-
ing a mirror image of the extended risk haplotype. Just as
the Oxford caseecontrol ascertainment could have ampli-
ﬁed sex differences, so also the Richmond hand OA panel
had a remarkable difference in sex distribution of cases and
controls. The overlap among Rotterdam index phenotypes
(Table I) gives a clue to how frequently hand OA overlaps
with knee and hip OA. Were the IL-1-hand OA association
true, one would expect that case panels collected by knee
and hip index phenotype could often include hand OA sub-
jects. This argues that genetic associations with hand OA
might be dimly or brightly reﬂected in case panels collected
by other index joints. Current and future genome-wide asso-
ciation efforts with complete phenotyping and substantial
statistical power may answer the question of IL-1 common
variant association with OA, but full phenotyping, multiple
replication among distinct panels, and statistical stringency
will be critical for ﬁnding true association. None of
these were achieved in the present study. Currently, rare
variant association would take a completely differentdeep-sequencing-based study design, but one can argue
that the IL-1 region does not yet contain credible candidates
to be targeted.Conﬂict of interest
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